-
-
-
-
-
-
-
Genmab Announces Financial Results for the First Quarter of 2024
-
-
-
-
-
-
-
Key Biotech Events to Watch, Week of 5/15/2023
-
-
-
-
-
-
-
Genmab A/S (GMAB) and Seagen (SGEN) Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin BLA for Patients with Recurrent or Metastatic Cervical Cancer
-
-
-
-
-
-
-
Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma
-
14,982 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

